{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:55:00Z","timestamp":1681448100601},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1675","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved Verkazia (Santen), a 0.1% ophthalmic emulsion formulation of the calcineurin inhibitor cyclosporine, for treatment of vernal keratoconjunctivitis (VKC). Verkazia is the first product to be approved in the US for this indication.<\/jats:p>","DOI":"10.58347\/tml.2023.1675d","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T19:23:34Z","timestamp":1681413814000},"page":"70-72","source":"Crossref","is-referenced-by-count":0,"title":["Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,5,1]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T19:23:34Z","timestamp":1681413814000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1675d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":0,"journal-issue":{"issue":"1675","published-online":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1675d","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}